Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market CAGR Analysis And Future Market Development
The market for primary progressive multiple sclerosis (PPMS) therapies has expanded quickly in recent years. It is projected to increase from $1.16 billion in 2025 to $1.31 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.7%. Historical expansion has been driven by factors such as the scarcity of treatment alternatives for PPMS, the dependence on corticosteroids to manage symptoms, limited patient awareness of the condition, underdeveloped hospital pharmacy systems, and the gradual uptake of immunosuppressants.
The primary progressive multiple sclerosis (PPMS) treatment market is poised for substantial expansion in the coming years. By 2030, its value is projected to reach $2.18 billion, reflecting a compound annual growth rate (CAGR) of 13.5%. This anticipated growth during the forecast period is driven by factors such as the launch of targeted monoclonal antibodies, heightened research and development efforts in neurodegenerative conditions, the broadening of hospital and online pharmacy networks, an increase in regulatory approvals for innovative treatments, and enhanced patient awareness coupled with early diagnosis initiatives. Key trends shaping this period include a growing preference for monoclonal antibodies in PPMS management, a stronger emphasis on alleviating symptoms and improving quality of life, a shift toward intravenous drug administration, the expansion of hospital and specialty pharmacy channels, and the continuous development of novel therapeutics and combination approaches.
Download A Free Sample Report For Comprehensive Market Insights:
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Growth Drivers: What Factors Are Accelerating Expansion?
The rising necessity for impactful therapies is anticipated to fuel expansion in the primary progressive multiple sclerosis (PPMS) treatment market moving ahead. Impactful therapies refer to medical approaches that alleviate symptoms, enhance patient outcomes, or eliminate a disease or condition. This growing necessity is largely propelled by the increasing occurrence of chronic and intricate health issues that call for sustained management and advanced medical solutions to boost patient results and life quality. By addressing inflammation and safeguarding neurological function, such therapies decelerate PPMS progression, thus elevating long-term life quality, curbing disability accumulation, and empowering individuals to handle daily tasks with greater autonomy and steadiness. For example, data from January 2024 released by the American Society of Gene & Cell Therapy—a US-focused organization dedicated to gene and cell therapy—showed that the number of gene therapies in Phase III clinical trials hit 33 in 2023, marking a 10% rise from 2022 and the first quarterly uptick since Q3 2022. Consequently, the escalating demand for impactful therapies is steering the growth of the primary progressive multiple sclerosis (PPMS) treatment market.
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Segment Landscape And Growth Potential
The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab
2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide
3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone
4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Trends: What Is Shaping Future Industry Growth?
Within the primary progressive multiple sclerosis (PPMS) treatment market, key players are placing significant emphasis on creating novel formulations, particularly monoclonal antibody drugs, aimed at improving multiple sclerosis care. These monoclonal antibody therapies function by specifically binding to immune cells or proteins responsible for triggering inflammation and neural damage, thereby minimizing disease activity and decelerating symptom progression. A concrete example is provided by Roche Pharma India, headquartered in India, which introduced Ocrevus (ocrelizumab) in February 2024 for treating multiple sclerosis (MS) within the country. Ocrevus distinguishes itself as the first and only approved disease-modifying therapy (DMT) that addresses both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the Indian market. Its mechanism of action involves targeting CD20-positive B cells—immune cells implicated in the aberrant immune responses characteristic of MS. Administration occurs through a twice-yearly intravenous infusion lasting just two hours, delivering a more convenient yet highly effective treatment alternative for patients.
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA
Access The Complete Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report:
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model